The study of Involvement of Adenosine Triphosphate in Sputum in Pathophysiology of Asthma
- Conditions
- Bronchial asthma, COPD
- Registration Number
- JPRN-UMIN000035749
- Lead Sponsor
- Saitama Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 215
Not provided
1) Patients who have exacerbations of asthma or COPD within the last 4 weeks a)Asthma exacerbation: oral corticosteroids administrated for more than 2 days because of having cough and sputum ,and/or more than 20% decrease of expiratory peak flow vales for consecutive 3 days b) COPD exacerbation: exhibition of increased shortness of breathing, increased cough and sputum that result in a change of treatment 2) Patients with allergic bronchial pulmonary aspergillosis or eosinophilic granulomatosis with polyangitis 3) Patients with following disorders: severe heart diseases, severe renal diseases, neurological diseases 4) Pregnancy or lactation 5) Patients who are considered unsuitable for enrollment in this study by physicians in charge
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Contribution of ATP in sputum to clinical pathophysiology in asthma Measure ATP in induced sputum to determine whether concentrations of them increase in patients with asthma.
- Secondary Outcome Measures
Name Time Method Association between ATP in sputum and following clinical parameters: severity, pulmonary function, cell counts in induced sputum, exhaled oxide concentrations, cytokines, chemokines, granule proteins